ECDC MISSION REPORT 19–21 September 2016 ; 14–15 November 2016
Int J Vaccines Vaccin 2016, 2(1): 00018, January 29, 2016
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s...tandardised questionnaires and the Global TB Drug Facility website.
more
The number of new Ebola infections in Sierra Leone is declining, despite the outbreak continuing to claim lives. New cases have dropped to around 9-12 per week, according to recent WHO figures. There were over 500 cases per week at the height of the crisis around late November 2014.
The impact on t...he lives of the thousands of people directly affected by the disease has been devastating. It has caused substantial suffering to many others, leaving the population very vulnerable.
more
Funded by CBM: www.cbm.org
Around the world, approximately 1 in 45 children are on the move – nearly 50 million boys and girls that have migrated across borders or been forcibly displaced within their own countries.1 Climate-related events
and their impacts are already contributing significantly to these staggering numbers...,with 14.7 million people facing new internal displacement as a result of weather-related disasters in 2015 alone. The annual average
since 2008 is higher still, at 21.5 million, equivalent to almost 2,500 people being displaced every single day.2
more
This Guidance Document provides practical assistance to Country Offices scaling up programmes to manage SAM in young children. It outlines a step-by-step process through which countries can analyse their current situation, identify barriers and bottlenecks through the MoRES approach, and plan action... to scale-up treatment. In particular it addresses the challenge of supporting governments to accelerate and sustain scale-up, build national capacities and source reliable and sustained supplies and financing for managing SAM. This document also provides complementary background information, references to international technical recommendations, resources and tools.
more
Clinical guideline, Methods, Evidence and Recommendations
In this guideline the following is covered: information needs of people with chronic hep
titis B and their carers; where children, young people and adults with chronic hepatitis B a-
should be assessed; assessment of liver disease, includi...ng the use of non-invasive tests and genotype testing; criteria for offering antiviral treatment; the efficacy, safety and cost effectiveness of currently available treatments; selection of first-line therapy; management of treatment failure or drug resistance; prophylactic treatment during im-
munosuppressive therapy; and monitoring for treatment response
more
An Infographic Guide to Technology-facilitated Gender-based Violence (TFGBV) offers a visually engaging toolkit designed to raise awareness and deepen understanding of the pervasive and harmful impact of TFGBV on women and girls in all their diversity.
Pathogens . 2021 Nov 16;10(11):1493.doi: 10.3390/pathogens10111493
.Chronic manifestations of Chagas disease present as disabling and life-threatening condi-tions affecting mainly the cardiovascular and gastrointestinal systems. Although meaningful research has outlined the different molecular mech...anisms underlying Trypanosoma cruzi’s infection and the host-parasite interactions that follow, prompt diagnosis and treatment remain a challenge, particu-larly in developing countries and also in those where the disease is considered non-endemic. This review intends to present an up-to-date review of the parasite’s life cycle, genetic diversity, virulence factors, and infective mechanisms, as well as the epidemiology, clinical presentation, diagnosis, and treatment options of the main chronic complications of Chagas disease.
more
Research and Reports in Tropical Medicine 2022:13 25–40.
Chagas disease (CD) is caused by the parasite Trypanosoma cruzi, and it is endemic in Central, South America, Mexico and the South of the United States. It is an important cause of early mortality and morbidity, and it is associated with po...verty and stigma. A third of the cases evolve into chronic cardiomyopathy and gastrointestinal disease. This review proposes strategies to address challenges faced by non-endemic countries
more